Danielle van Oosbree
Nurse Practitioner · Ankeny, IANPI 1184395162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$828
- Otsuka America Pharmaceutical, Inc.$793
- Teva Pharmaceuticals USA, Inc.$404
- Lundbeck LLC$369
- Alkermes, Inc.$357
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$312
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,093100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,101 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $317,995 |
| RexultiBrexpiprazole | 123 | $183,212 |
| VraylarCariprazine Hcl | 122 | $171,103 |
| Invega SustennaPaliperidone Palmitate | 51 | $169,389 |
| AristadaAripiprazole Lauroxil | 41 | $126,829 |
| Austedo XrDeutetrabenazine | 16 | $109,256 |
| LybalviOlanzapine/Samidorphan Malate | 54 | $85,186 |
| TrintellixVortioxetine Hydrobromide | 147 | $72,322 |
| CaplytaLumateperone Tosylate | 42 | $70,046 |
| FanaptIloperidone | 25 | $56,602 |
| UzedyRisperidone | 18 | $48,193 |
| Loreev XrLorazepam | 78 | $26,765 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $26,249 |
| DayvigoLemborexant | 55 | $17,928 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $17,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $293 | $317,99539 claims |
| Alkermes, Inc.Aristada, Lybalvi | $357 | $212,01595 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $793 | $183,212123 claims |
| AbbVieVraylar | $828 | $171,103122 claims |
| Johnson & JohnsonInvega Sustenna | $299 | $169,38951 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $404 | $157,44934 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $32 | $88,474188 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $312 | $70,04642 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $177 | $56,60225 claims |
| Almatica Pharma LLCLoreev Xr | $266 | $26,76578 claims |
| Axsome Therapeutics, Inc.Auvelity | $167 | $17,74616 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $54 | $12,23623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Ankeny
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
- Michaela JohnsonWaterloo$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.